source
- FDA clears Bristol Myers' Zenbexus, first drug of a new class for advanced multiple myelomaThe FDA announced approval of an oral therapy from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug, iberdomide, will be marketed as Zenbexus and is intended to be used t…
- Silence Therapeutics' Phase 2 trial shows strong results for divesiran in polycythemia vera, shares jump 30%Silence Therapeutics reported that its nucleic‑acid drug divesiran achieved a 69% placebo‑adjusted response rate in a Phase 2 study of polycythemia vera patients. Safety was reported as clean, with…